Teens Unaware Of The Dangers Of AIDS.
The import that AIDS is having on American kids has improved greatly in brand-new years, thanks to productive drugs and prevention methods. The same cannot be said, however, for children worldwide. "Maternal-to-child carrying is down exponentially in the United States because we do a good job at preventing it," said Dr Kimberly Bates, chairman of a clinic for children and families with HIV/AIDS at Nationwide Children's Hospital in Columbus, Ohio.
In fact, the chances of a mollycoddle contracting HIV from his or her mother is now less than 1 percent in the United States, according to the US Centers for Disease Control and Prevention. Still, concerns exist. "In a subset of teens, the or slue of infections are up. We've gotten very usefulness at minimizing the stain and treating HIV as a chronic disease, but what goes away with the acceptance is some of the messaging that heightens awareness of risk factors.
Today, multitude are very unclear about what their actual risk is, especially teens". Increasing awareness of the risk of HIV, the virus that causes AIDS, is one purpose that health experts hope to attain. Across the globe, the AIDS growth has had a harsher effect on children, especially those in sub-Saharan Africa. According to the World Health Organization, about 3,4 million children worldwide had HIV at the end of 2011, with 91 percent of them living in sub-Saharan Africa.
Children with HIV/AIDS regularly acquired it from HIV-infected mothers during pregnancy, emergence or breast-feeding. Interventions that can up the odds of mother-to-child transmission of HIV aren't widely available in developing countries. And, the care that can keep the virus at bay - known as antiretroviral cure - isn't available to the majority of kids living with HIV. Only about 28 percent of children who have occasion for this treatment are getting it, according to the World Health Organization.
In the United States, however, the prospect for a child or teen with HIV is much brighter. "Every time we stop to have a discussion about HIV, the release gets better. The medications are so much simpler, and they can prevent the complications. Although we don't recognize for sure, we anticipate that most teens with HIV today will live a normal life span, and if we get to infants with HIV early, the assumption is that they'll have a regular life span". For kids, though, living with HIV still isn't easy.
And "The toughest department for most young common people is the knowledge that, no matter what, they have to be on medications for the rest of their lives. If you miss a measure of diabetes medication, your blood sugar will go up, but then once you take your medicine again, it's fine. If you slip-up HIV medication, you can become resistant". The medications also are pricey. However a federal program made imaginable by the Ryan White CARE Act helps people who can't pay their medication get help paying for it.
Showing posts with label medication. Show all posts
Showing posts with label medication. Show all posts
Sunday 16 February 2020
Thursday 26 December 2019
Treatment Of Depression Or ADHD
Treatment Of Depression Or ADHD.
Slightly more than 6 percent of US teens crook medicine medications for a mental health condition such as depression or attention-deficit/hyperactivity disturbance (ADHD), a new survey shows. The survey also revealed a wide gap in psychiatric downer use across ethnic and racial groups. Earlier studies have documented a rise in the use of these medications in the midst teens, but they mainly looked at high-risk groups such as children who have been hospitalized for psychiatric problems. The altered survey provides a snapshot of the number of adolescents in the general population who took a psychiatric narcotize in the past month from 2005 to 2010.
Teens aged 12 to 19 typically took drugs to prescribe for depression or ADHD, the two most common mental health disorders in that era group. About 4 percent of kids aged 12 to 17 have experienced a meet of depression, the study found. Meanwhile, 9 percent of children aged 5 to 17 have been diagnosed with ADHD, a behavioral mess marked by difficulty paying attention and impulsive behavior.
Males were more reasonable to be taking medication to treat ADHD, while females were more commonly taking medication to treat depression. This follows patterns seen in the diagnosis of these conditions across genders. Exactly what is driving the rejuvenated numbers is not clear, but "in my opinion, it's an enlargement in the diagnosis of various conditions that these medications can be prescribed for," said burn the midnight oil author Bruce Jonas.
He is an epidemiologist at the US Centers for Disease Control and Prevention's National Center for Health Statistics (NCHS). But these are stressful times and it is also admissible that children are comely more vulnerable to these conditions as a result. "The recession and various world events might be a contributing factor," Jonas speculated. "Adolescents and children do accept psychiatric medications.
Slightly more than 6 percent of US teens crook medicine medications for a mental health condition such as depression or attention-deficit/hyperactivity disturbance (ADHD), a new survey shows. The survey also revealed a wide gap in psychiatric downer use across ethnic and racial groups. Earlier studies have documented a rise in the use of these medications in the midst teens, but they mainly looked at high-risk groups such as children who have been hospitalized for psychiatric problems. The altered survey provides a snapshot of the number of adolescents in the general population who took a psychiatric narcotize in the past month from 2005 to 2010.
Teens aged 12 to 19 typically took drugs to prescribe for depression or ADHD, the two most common mental health disorders in that era group. About 4 percent of kids aged 12 to 17 have experienced a meet of depression, the study found. Meanwhile, 9 percent of children aged 5 to 17 have been diagnosed with ADHD, a behavioral mess marked by difficulty paying attention and impulsive behavior.
Males were more reasonable to be taking medication to treat ADHD, while females were more commonly taking medication to treat depression. This follows patterns seen in the diagnosis of these conditions across genders. Exactly what is driving the rejuvenated numbers is not clear, but "in my opinion, it's an enlargement in the diagnosis of various conditions that these medications can be prescribed for," said burn the midnight oil author Bruce Jonas.
He is an epidemiologist at the US Centers for Disease Control and Prevention's National Center for Health Statistics (NCHS). But these are stressful times and it is also admissible that children are comely more vulnerable to these conditions as a result. "The recession and various world events might be a contributing factor," Jonas speculated. "Adolescents and children do accept psychiatric medications.
Diverting A Nurse In The Preparation Of Medicines Increases The Risk Of Errors
Diverting A Nurse In The Preparation Of Medicines Increases The Risk Of Errors.
Distracting an airline airman during taxi, takeoff or deplaning could chief to a critical error. Apparently the same is true of nurses who prepare and administer medication to health centre patients. A new study shows that interrupting nurses while they're tending to patients' medication needs increases the chances of error.
As the sum of distractions increases, so do the number of errors and the endanger to patient safety. "We found that the more interruptions a nurse received while administering a drug to a determined patient, the greater the risk of a serious error occurring," said the study's lead author, Johanna I Westbrook, commander of the Health Informatics Research and Evaluation Unit at the University of Sydney in Australia.
For instance, four interruptions in the lecture of a single drug administration doubled the probability that the patient would experience a major mishap, according to the study, reported in the April 26 efflux of the Archives of Internal Medicine. Experts say the study is the first to show a clear association between interruptions and medication errors.
It "lends mighty evidence to identifying the contributing factors and circumstances that can bring to a medication error," said Carol Keohane, program director for the Center of Excellence for Patient Safety Research and Practice at Brigham and Women's Hospital in Boston. "Patients and blood members don't agree that it's dangerous to patient safety to interrupt nurses while they're working," added Linda Flynn, secondary professor at the University of Maryland School of Nursing in Baltimore. "I have seen my own family tree members go out and interrupt the nurse when she's standing at a medication haul to ask for an extra towel or something else inappropriate".
Julie Kliger, who serves as program director of the Integrated Nurse Leadership Program at the University of California, San Francisco, said that administering medication has become so stereotypic that Dick involved - nurses, health-care workers, patients and families -- has become complacent. "We requirement to reframe this in a new light, which is, it's an important, deprecating function. We need to give it the respect that it is due because it is high volume, high risk and, if we don't do it right, there's determined harm and it costs money".
Distracting an airline airman during taxi, takeoff or deplaning could chief to a critical error. Apparently the same is true of nurses who prepare and administer medication to health centre patients. A new study shows that interrupting nurses while they're tending to patients' medication needs increases the chances of error.
As the sum of distractions increases, so do the number of errors and the endanger to patient safety. "We found that the more interruptions a nurse received while administering a drug to a determined patient, the greater the risk of a serious error occurring," said the study's lead author, Johanna I Westbrook, commander of the Health Informatics Research and Evaluation Unit at the University of Sydney in Australia.
For instance, four interruptions in the lecture of a single drug administration doubled the probability that the patient would experience a major mishap, according to the study, reported in the April 26 efflux of the Archives of Internal Medicine. Experts say the study is the first to show a clear association between interruptions and medication errors.
It "lends mighty evidence to identifying the contributing factors and circumstances that can bring to a medication error," said Carol Keohane, program director for the Center of Excellence for Patient Safety Research and Practice at Brigham and Women's Hospital in Boston. "Patients and blood members don't agree that it's dangerous to patient safety to interrupt nurses while they're working," added Linda Flynn, secondary professor at the University of Maryland School of Nursing in Baltimore. "I have seen my own family tree members go out and interrupt the nurse when she's standing at a medication haul to ask for an extra towel or something else inappropriate".
Julie Kliger, who serves as program director of the Integrated Nurse Leadership Program at the University of California, San Francisco, said that administering medication has become so stereotypic that Dick involved - nurses, health-care workers, patients and families -- has become complacent. "We requirement to reframe this in a new light, which is, it's an important, deprecating function. We need to give it the respect that it is due because it is high volume, high risk and, if we don't do it right, there's determined harm and it costs money".
Wednesday 1 June 2016
New Blood Thinner Pill For Patients With Deep Vein Thrombosis
New Blood Thinner Pill For Patients With Deep Vein Thrombosis.
A unknown anti-clotting pill, rivaroxaban (Xarelto), may be an effective, useful and safer curing for patients coping with deep-vein thrombosis (DVT), a pair of new studies indicate. According to the research, published online Dec 4, 2010 in the New England Journal of Medicine, the hypnotic could sell a new option for these potentially life-threatening clots, which most typically look in the lower leg or thigh. The findings are also slated for presentation Saturday at the annual session of the American Society of Hematology (ASH), in Orlando, Fla.
And "These study outcomes may if possible change the way that patients with DVT are treated," study author Dr Harry R Buller, a professor of prescription at the Academic Medical Center at the University of Amsterdam, said in an ASH message release. "This new treatment regimen of oral rivaroxaban can potentially do blood clot therapy easier than the current standard treatment for both the patient and the physician, with a single-drug and unassuming fixed-dose approach".
Another heart expert agreed. "Rivaroxiban is at least as effective as the older dose warfarin and seems safer. It is also far easier to use since it does not require blood testing to acclimate the dose," said cardiologist Dr Alan Kadish, currently president of Touro College in New York City.
The mug up was funded in part by Bayer Schering Pharma, which markets rivaroxaban furthest the United States. Funding also came from Ortho-McNeil, which will market the drug in the United States should it bring in US Food and Drug Administration approval. In March 2009, an FDA admonitory panel recommended the drug be approved, but agency review is ongoing pending further study.
The authors note that upwards of 2 million Americans endure a DVT each year. These limb clots - sometimes called "economy flight syndrome" since they've been associated with the immobilization of yearn flights - can migrate to the lungs to form potentially deadly pulmonary embolisms. The widely known standard of care typically involves treatment with relatively well-known anti-coagulant medications, such as the vocalized medication warfarin (Coumadin) and/or the injected medication heparin.
While effective, in some patients these drugs can fast unstable responses, as well as problematic interactions with other medications. For warfarin in particular, the quiescent also exists for the development of severe and life-threatening bleeding. Use of these drugs, therefore, requires deep and continuous monitoring. The search for a safer and easier to administer care option led Buller's team to analyze two sets of data: One that eroded rivaroxaban against the standard anti-clotting drug enoxaparin (a heparin-type medication), and the second which compared rivaroxaban with a placebo.
A unknown anti-clotting pill, rivaroxaban (Xarelto), may be an effective, useful and safer curing for patients coping with deep-vein thrombosis (DVT), a pair of new studies indicate. According to the research, published online Dec 4, 2010 in the New England Journal of Medicine, the hypnotic could sell a new option for these potentially life-threatening clots, which most typically look in the lower leg or thigh. The findings are also slated for presentation Saturday at the annual session of the American Society of Hematology (ASH), in Orlando, Fla.
And "These study outcomes may if possible change the way that patients with DVT are treated," study author Dr Harry R Buller, a professor of prescription at the Academic Medical Center at the University of Amsterdam, said in an ASH message release. "This new treatment regimen of oral rivaroxaban can potentially do blood clot therapy easier than the current standard treatment for both the patient and the physician, with a single-drug and unassuming fixed-dose approach".
Another heart expert agreed. "Rivaroxiban is at least as effective as the older dose warfarin and seems safer. It is also far easier to use since it does not require blood testing to acclimate the dose," said cardiologist Dr Alan Kadish, currently president of Touro College in New York City.
The mug up was funded in part by Bayer Schering Pharma, which markets rivaroxaban furthest the United States. Funding also came from Ortho-McNeil, which will market the drug in the United States should it bring in US Food and Drug Administration approval. In March 2009, an FDA admonitory panel recommended the drug be approved, but agency review is ongoing pending further study.
The authors note that upwards of 2 million Americans endure a DVT each year. These limb clots - sometimes called "economy flight syndrome" since they've been associated with the immobilization of yearn flights - can migrate to the lungs to form potentially deadly pulmonary embolisms. The widely known standard of care typically involves treatment with relatively well-known anti-coagulant medications, such as the vocalized medication warfarin (Coumadin) and/or the injected medication heparin.
While effective, in some patients these drugs can fast unstable responses, as well as problematic interactions with other medications. For warfarin in particular, the quiescent also exists for the development of severe and life-threatening bleeding. Use of these drugs, therefore, requires deep and continuous monitoring. The search for a safer and easier to administer care option led Buller's team to analyze two sets of data: One that eroded rivaroxaban against the standard anti-clotting drug enoxaparin (a heparin-type medication), and the second which compared rivaroxaban with a placebo.
Subscribe to:
Posts (Atom)